M&A Deal Summary

Callitas Therapeutics Acquires RX Global Capital

On April 28, 2015, Callitas Therapeutics acquired medical products company RX Global Capital

Acquisition Highlights
  • This is Callitas Therapeutics’ 2nd transaction in the Medical Products sector.
  • This is Callitas Therapeutics’ 2nd transaction in Canada.
  • This is Callitas Therapeutics’ 1st transaction in British Columbia.

M&A Deal Summary

Date 2015-04-28
Target RX Global Capital
Sector Medical Products
Buyer(s) Callitas Therapeutics
Deal Type Add-on Acquisition

Target

RX Global Capital

British Columbia, Canada
RX Global Capital, Inc. is a developer of controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss, and several other medical applications.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Callitas Therapeutics

Vancouver, British Columbia, Canada

Category Company
Founded 2003
Sector Healthcare Services
Revenue 1M CAD (2017)
DESCRIPTION

Callitas Health is focuses on providing biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes. Callitas Health was founded in 2003 and is based in Vancouver, Canada.


DEAL STATS #
Overall 2 of 4
Sector (Medical Products) 2 of 2
Type (Add-on Acquisition) 2 of 3
State (British Columbia) 1 of 1
Country (Canada) 2 of 2
Year (2015) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-19 M Diagnostics

Calgary, Alberta, Canada

M Diagnostics, Inc. is a manufacturer of eMosquito monitoring devices to measure blood glucose, primarily by diabetics.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-01 Chelatexx - Reformulated Orlistat For Weight Loss

United States

Chelatexx - Reformulated Orlistat For Weight Loss comprises a weight loss pharmaceutical product. The asset is located in the United States.

Buy -